Vu L. Truong, Ph.D.
Founder, Chief Executive Officer and Director
Dr. Truong is a founder of Aridis and was elected CEO in 2014 after having served as the company’s Chief Scientific Officer since 2005.
He has more than 20 years of experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to MedImmune) and MedImmune (sold to Astra Zeneca). Having maintained a life-long interest in infectious diseases, he has focused on researching and developing innovative human monoclonal antibodies and vaccines designed to address life-threatening infections. His product development experience includes FluMist™, Synagis™ mAb and a number of other monoclonal antibody-based therapeutics. Dr. Truong is the principal architect of Aridis’ technologies, which includes a range of anti-infective products and pharmaceutical processing technologies. He received his Ph.D. in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.
Paul Mendelman, M.D.
Interim Chief Medical Officer
Dr. Mendelman brings to Aridis a prolific career in infectious diseases across industry and academia spanning over 30 years with board certification in infectious diseases.
He has held senior clinical development positions at leading companies such as Takeda Vaccines (Vice President, Medical), MedImmune (Vice President & Therapeutic Area Leader, Clinical Development), and Merck (Director, Clinical Research Infectious Diseases). He earned his BS and MD degrees at The Ohio State University, and completed post-graduate training at the University of Colorado Medical Center in Denver. His infectious disease fellowship at the University of Washington, School of Medicine, and Seattle Children’s Hospital was followed by his joining that faculty and later serving as consulting Professor of Pediatrics, at Stanford University School of Medicine. He has published over 100 articles in peer-reviewed journals and authored several published book chapters.
Fred Kurland, J.D., M.B.A.
Chief Financial Officer
Mr. Kurland has more than 35 years of experience in corporate finance, most recently as the CFO of Xoma.
Mr. Kurland has a long and distinguished career as Chief Financial Officer of a number of biotechnology companies including Bayhill Therapeutics, Corcept Therapeutics, Genitope Corporation, Aviron, Protein Design Labs and Applied Immune Sciences, Inc. Previously, he held a number of financial management positions at Syntex Corporation between 1981 and 1995 including Vice President and Controller between 1991 and 1995. Mr. Kurland received his B.S. from Lehigh University and his J.D. and M.B.A. degrees from the University of Chicago.
Steven Chamow, Ph.D.
Vice President of Research and Development
Dr. Chamow has more than 25 years of experience in biopharmaceutical product development and contributed to the development of three marketed products (Avastin, Natrecor, Vectibix).
He served in leadership positions at a number of leading biotech companies, including Senior Vice President at Intradigm and Vice President of Process Sciences at Genitope Corporation and at Abgenix, Inc. (acquired by Amgen). He was also a senior scientist at Genentech. Dr. Chamow is author or co-author of more than 50 scientific publications and patents and co-editor of two books on therapeutic antibody fusion proteins. He received his Ph.D. in biochemistry at University of California, Davis.
Elizabeth Leininger, Ph.D.
Vice President of Regulatory Affairs
Dr. Leininger is an expert in regulatory affairs and quality, with more than 20 years of experience at CBER/FDA and at biopharmaceutical companies.
She previously held senior management positions at Chiron (acquired by Novartis) and GSK. Additionally, she has significant expertise in global strategic development, licensing and post-marketing regulatory activities for biological and biotechnology products. She also ran large QA/QC organizations responsible for the evaluation, development and implementation of Quality Systems, including documentation, training and auditing. Dr. Leininger earned her Ph.D. in chemistry from the University of North Carolina at Chapel Hill.
Mitchell H Rosner, Ph.D.
Vice President of Quality
Mitchell H Rosner has more than 25 years’ experience in biotechnology and pharmaceutical companies in Pharmaceutics, Analytical Chemistry and Quality.
He has contributed to several approved products (Rituxan, Zevalin, Ranexa, Lexiscan, Exubera, Tobi Podhaler and Astaxanthin) and has multiple patents. Mitch began his industrial career at IDEC Pharmaceuticals (now Biogen) and held positions where he led Quality Control and Analytics for CV Therapeutics (now Gilead Sciences), Nektar Therapeutics, Novartis (San Carlos) and Algenol Biotechnology. More recently he headed Quality at Synthetic Genomics. Mitch received his Ph.D. in Pharmacology and Toxicology (1989) from the University of Arizona and has several professional certifications in Quality.
Jeffrey J. Fessler, J.D.
Acting General Counsel
Mr. Fessler has more than 20 years of experience providing corporate and securities legal counsel in the biotechnology industry.
He has extensive experience providing counsel in public offerings and private placements as well as mergers and acquisitions, joint ventures, proxy contests, restructurings, and private equity and debt financings. He is a partner in the Sheppard Mullin law firm and has practiced corporate and securities law at several large firms, including Akin, Gump, Strauss, Hauer & Feld and Orrick, Herrington & Sutcliffe, and Sichenzia Ross Friedman Ference LLP. Mr. Fessler holds a B.S. degree in Accounting from the University of Maryland and J.D. (magna cum laude) from New York Law School.